Showing 2691-2700 of 4954 results for "".
- Dermatologist Lynette J. Margesson, MD Recognized as NAPW Woman of the Yearhttps://practicaldermatology.com/news/20140624-dermatologist_lynette_j_margesson_md_recognized_as_napw_woman_of_the_year/2459193/The National Association of Professional Women (NAPW) honored Lynette J. Margesson, MD of Danby & Margesson Dermatologists, as a 2014 Professional Woman of the Year. Dr. Margesson is recognized with this prestigious distinction for leadership in medicine.
- Spain's LETI Laboratories Launches Leading Atopic Skincare Line to U.S. Markethttps://practicaldermatology.com/news/20140617-spains_leti_laboratories_launches_leading_atopic_skincare_line_to_us_market/2459203/DermWORX Professional Skincare and LETI Laboratories, headquartered in Barcelona, Spain, will launch a series of top European dermatological products in the United States. The series includes: LETI's leading dermatology line for atopic skin, AT4, which DermWORX will market to U.S. heal
- Two States Pass Laws Banning Indoor Tanning for Minorshttps://practicaldermatology.com/news/20140527-two_states_pass_laws_banning_indoor_tanning_for_minors/2459230/Minnesota and Louisiana have both recently passed legislation banning the use of indoor tanning facilities for those under 18 years of age. Both laws go into effect on August 1, 2014. Nine states in total have instituted bans on indoor tanning for minors, including Vermont, California, Illinois, Ore
- mysoscience Launches Novel Pain Treatmenthttps://practicaldermatology.com/news/20140516-mysoscience_launches_novel_pain_treatment/2459238/myoscience, inc., has launched ioveradegrees, a new option to immediately block pain using the body's natural response to cold without the use of drugs or surgery. The ioveradegrees health treatment utilizes myoscience's platform technology—the Focused Cold Therapy(TM) delivery system—to precisely t
- Aldeyra Therapeutics' Lead Candidate NS2 Shows Novel Approach to Treating Dry Skin, Eye Diseaseshttps://practicaldermatology.com/news/20140512-aldeyra_therapeutics_lead_candidate_ns2_shows_novel_approach_to_treating_dry_skin_eye_diseases/2459242/Aldeyra Therapeutics' lead candidate NS2 decreases aldehyde levels in dry skin and eye models, according to data to be presented as an abstract poster at the Society for Investigative Dermatology (SID) 2014 Annual Meeting, in Albuquerque, NM. The study found that topical applicat
- Researchers Examine UV Nail Salon Lamps and Risk of Skin Cancerhttps://practicaldermatology.com/news/20140501-researchers_examine_uv_nail_salon_lamps_and_risk_of_skin_cancer/2459249/A recent research letter in JAMA Dermatology stated that although using higher-wattage ultra violet (UV) lamps at nail salons to dry and c
- ALPHAEON Launches New Patient Financing Solutionhttps://practicaldermatology.com/news/20140425-alphaeon_launches_new_patient_financing_solution/2459256/ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings, LLC, launched ALPHAEON CREDIT, which the company describes as a new tool for patients seeking to finance self-pay lifestyle healthcare procedures through board-certified specialty physicians in dermatology, ophthalmology, plast
- LovelySkin.com Awarded Patent for Skin Care Product Designed to Heal While Moisturizing Dry Lips and Skinhttps://practicaldermatology.com/news/20140423-lovelyskincom_awarded_patent_for_skin_care_product_designed_to_heal_while_moisturizing_dry_lips_and_skin/2459259/Joel Schlessinger, MD (owner of LovelySkin.com) and his son, Daniel, were just awarded the patent for FixMySkin 1% hydrocortisone balm—a suite of products specifically designed to heal, not ju
- Dermatologist Launches Kickstarter Campaignhttps://practicaldermatology.com/news/20140422-dermatologist_launches_kickstarter_campaign/2459261/Steven Feldman, MD, PhD, is spearheading a new Kickstarter campaign entitled “Changes in the Landscape” for the Coalition for Peace and Justice, an organization that welcomes all individuals and g
- Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lineshttps://practicaldermatology.com/news/20140421-revance_therapeutics_announces_positive_results_from_the_rt002_phase_12_study_in_glabellar_frown_lines/2459262/Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the treatment of moderate to severe glabellar (frown) lines. RT002 is Revance's proprietary, injectable botulinum toxin investigational product that incorpo